---

---

tags : Trial    source : Www.biospace.com   

save search

---

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K |

n/a

| -22.34% | O: -7.45% H: 0.0% C: 0.0%
hepatitis vaccine license granted biopharma virus trial

---

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $17.65 -2.4% 4K |

Health Technology

| 2.02% | O: -0.87% H: 3.58% C: -2.86%
nephropathy congress world nefecon trial therapeutics

---

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K |

Health Technology

| 40.08% | O: 5.41% H: 41.06% C: 29.66%
bb-301 first positive biopharma for trial opmd study

---

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K |

Health Technology

| 0.84% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

---

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.15 1.58% 1.55% 64K |

Health Technology

| -4.1% | O: -2.42% H: 0.0% C: 0.0%
allonk first candidate lupus cell trial therapy

---

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M |

Health Technology

| -0.6% | O: 1.22% H: 0.21% C: -0.34%
vent-02 trial therapeutics results

---

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.65 -2.72% -2.8% 71K |

Manufacturing

| -6.1% | O: -1.22% H: 0.0% C: -2.06%
symposium topline medical trial

---

QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
GIA | $1.08 237.96% 1.4K |

| Email alert Add to watchlist
breast technology trial imaging

---

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
PTCHF | $2.78 19.97% 560 |

n/a

| Email alert Add to watchlist
lyt-100 fibrosis trial

---

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.23 -4.03% 120K |

Manufacturing

| Email alert Add to watchlist
free breast cancer medical trial results

---

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K |

Health Technology

| -3.76% | O: -8.14% H: 19.55% C: 18.18%
conference treatment pharmaceuticals for trial response

---

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M |

Health Technology

| -81.65% | O: -75.4% H: 5.41% C: -29.73%
first update pharmaceuticals trial financial results

---

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -0.21% | O: -0.04% H: 0.0% C: 0.0%
avb-101 first dementia for trial

---

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M |

Health Technology

| -7.15% | O: -1.01% H: 2.04% C: 1.17%
ajovy for teva trial migraine china results

---

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320 |

Communications

| -1.12% | O: -100.0% H: NaN% C: Infinity%
GILD | $66.77 0.92% 0.91% 11M |

Health Technology

| -2.0% | O: 0.5% H: 0.83% C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M |

Health Technology

| -11.79% | O: 2.33% H: 2.28% C: -4.23%
hope treatment pharmaceuticals city for car-t trial

---

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Published: 2024-04-11 (Crawled : 17:00) - biospace.com/
KPRX | $0.502 -1.57% -1.59% 49K |

Manufacturing

| -17.62% | O: 3.23% H: 0.16% C: -1.79%
granted approval pharmaceuticals research for grant trial foundation study

---

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| 1.85% | O: 1.85% H: 0.0% C: 0.0%
biotech fda breast cancer for meeting trial submission

---

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04
Published: 2024-04-10 (Crawled : 14:30) - biospace.com/
ADIL | $1.9 -12.44% -14.21% 310K |

Health Technology

| 67.83% | O: 123.48% H: 0.0% C: 0.0%
ad04 publication pharmaceuticals trial

---

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Published: 2024-04-10 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M |

| -29.96% | O: -2.62% H: 1.92% C: -5.38%
amx0035 control pancreatic ongoing pharmaceuticals trial

---

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M |

Health Technology

| -24.02% | O: -2.31% H: 3.86% C: -1.47%
ser-155 for trial therapeutics

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---